Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA Locations section with a Washington entry has been added, improving visibility of where the study is conducted. The previous 'Washington Locations' entry and the HHS Vulnerability Disclosure have been removed.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedPublications description updated to indicate that items are automatically filled from PubMed and may not be about the study, and the Revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedRemoved the funding/operating status notice from the page. The study details and related information remain unchanged.SummaryDifference0.3%

- Check58 days agoChange DetectedBoth screenshots show the same page sections and information for Study NCT03331341; no additions or deletions are evident.SummaryDifference0.4%

- Check86 days agoChange Detected- Added a government funding notice and operating status guidance, plus a pointer to cc.nih.gov; - Bumped version from v3.1.0 to v3.2.0.SummaryDifference3%

- Check94 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.